Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients
|Title: ||Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients|
|Authors: ||Naya, Masanao Browse this author|
|Tsukamoto, Takahiro Browse this author|
|Morita, Koichi Browse this author|
|Katoh, Chietsugu Browse this author|
|Furumoto, Tomoo Browse this author|
|Fujii, Satoshi Browse this author|
|Tamaki, Nagara Browse this author|
|Tsutsui, Hiroyuki Browse this author →KAKEN DB|
|Keywords: ||coronary endothelial function|
|positron emission tomography|
|Issue Date: ||18-Sep-2007|
|Publisher: ||Elsevier Inc.|
|Journal Title: ||Journal of the American College of Cardiology|
|Start Page: ||1144|
|End Page: ||1149|
|Publisher DOI: ||10.1016/j.jacc.2007.06.013|
|Abstract: ||Objectives: We aimed to compare the effects of angiotensin II receptor blocker (ARB) olmesartan versus calcium channel blocker (CCB) amlodipine on coronary endothelial dysfunction in patients with hypertension.
Background: ARB is thought to have greater beneficial effects on coronary vasomotion via directly blocking action of angiotensin II than CCB.
Methods: Twenty-sex patients with untreated essential hypertension were prospectively assigned to the treatment with either olmesartan (27.7±12.4 mg per day, n=13) or amlodipine (5.6±1.5 mg per day, n=13) for 12 weeks. Changes of corrected myocardial blood flow (ΔMBF) and coronary vascular resistance (ΔCVR) from rest to cold pressor were measured by using 15O-water and positron emission tomography before and after treatment. Blood biomarkers including lipids, glucose, insulin, hs-CRP, interleukin-6, tumor necrosis factor-α, and superoxide dismutase (SOD) were also measured.
Results: Olmesartan and amlodipine reduced blood pressure (BP) to the same extent (−28.7±16.2 vs. −26.7±10.8 mmHg). In olmesartan group, ΔMBF tended to be greater (−0.15±0.19 vs. 0.03±0.17 ml/g/min, P=0.09 by 2-way ANOVA) and ΔCVR was significantly decreased (7.9±23.5 vs. −16.6±18.0 mmHg/[ml/g/min], P<0.05) after treatment whereas they did not change in amlodipine group (ΔMBF: −0.15±0.12 vs. −0.12±0.20 ml/g/min; ΔCVR: 6.5±18.2 vs. 4.8±23.4 mmHg/[ml/g/min]). Serum SOD activity tended to increase (4.74±4.77 vs. 5.57±4.74 U/ml, P=0.07 by 2-way ANOVA) only in olmesartan group.
Conclusions: Olmesartan, but not amlodipine, improved endothelium-dependent coronary dilation in hypertensive patients independently of BP lowering. These beneficial effects on coronary vasomotion might be via an antioxidant property of ARBs.|
|Type: ||article (author version)|
|Appears in Collections:||医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)|
Submitter: 納谷 昌直